(Q37971830)

26 August 2017

title

Exogenous glucagon-like peptide-1 for hyperglycemia in critically ill patients (English)

1 reference

26 August 2017

1 reference

Nicole R Pinelli

1

1 reference

26 August 2017

Mathew C Jones

2

1 reference

26 August 2017

Lea M Monday

3

1 reference

26 August 2017

Zachary Smith

4

1 reference

26 August 2017

Denise H Rhoney

5

1 reference

26 August 2017

language of work or name

English

0 references

publication date

27 December 2011

1 reference

Annals of Pharmacotherapy

26 August 2017

published in

1 reference

26 August 2017

volume

46

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

124-129

1 reference

Stress-induced hyperglycemia

26 August 2017

cites work

1 reference

Intensive insulin therapy in critically ill patients

21 January 2018

1 reference

Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data

21 January 2018

1 reference

Intensive insulin therapy in the medical ICU.

21 January 2018

1 reference

Intensive insulin therapy and pentastarch resuscitation in severe sepsis

21 January 2018

1 reference

Variability of blood glucose concentration and short-term mortality in critically ill patients

21 January 2018

1 reference

The incretin system and its role in type 2 diabetes mellitus

21 January 2018

1 reference

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

21 January 2018

1 reference

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

21 January 2018

1 reference

Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes

21 January 2018

1 reference

Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.

21 January 2018

1 reference

Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes

21 January 2018

1 reference

Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes

21 January 2018

1 reference

The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study

21 January 2018

1 reference

Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes

21 January 2018

1 reference

Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia

21 January 2018

1 reference

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1Q417

1 reference

26 August 2017

1 reference